
Patient Survey - PKD - INESSS |
Hello,
We would like to thank you for your participation in this short survey. The estimated time to complete it is approximately 5-7 minutes. The goal behind this survey is to better understand your reality as a patient living with polycystic kidney disease (PKD) and more precisely autosomal dominant polycystic kidney disease (ADPKD), as well as the underlying challenges. The survey will be conducted confidentially and will respect the anonymity of respondents. The data collected will be submitted to the INESSS (Institut national d’excellence en santé et en services sociaux), the provincial entity responsible for evaluating for public funding medications in Quebec.
The objective of this survey is to demonstrate that patients may benefit from a better access to tolvaptan, the only treatment option available for ADPKD.
Thank you for your time and collaboration on this initiative. You are helping to strengthen equal access to treatment options for patients living with ADPKD in Quebec.
------------------------------------------------------------
*Kindly note that the remainder of the survey will focus on autosomal dominant polycystic kidney disease and will be referred to as ‘ADPKD’.
We would like to thank you for your participation in this short survey. The estimated time to complete it is approximately 5-7 minutes. The goal behind this survey is to better understand your reality as a patient living with polycystic kidney disease (PKD) and more precisely autosomal dominant polycystic kidney disease (ADPKD), as well as the underlying challenges. The survey will be conducted confidentially and will respect the anonymity of respondents. The data collected will be submitted to the INESSS (Institut national d’excellence en santé et en services sociaux), the provincial entity responsible for evaluating for public funding medications in Quebec.
The objective of this survey is to demonstrate that patients may benefit from a better access to tolvaptan, the only treatment option available for ADPKD.
Thank you for your time and collaboration on this initiative. You are helping to strengthen equal access to treatment options for patients living with ADPKD in Quebec.
------------------------------------------------------------
*Kindly note that the remainder of the survey will focus on autosomal dominant polycystic kidney disease and will be referred to as ‘ADPKD’.